Business Context and Reporting Period
This Form 8-K was filed by Artelo Biosciences, Inc. on February 5, 2026, reporting events occurring on February 2, 2026. The filing addresses the Company's status regarding its listing on The Nasdaq Stock Market LLC (Nasdaq) following a hearing before the Nasdaq Hearing Panel.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The primary financial metric referenced is the Stockholders' Equity Rule (Nasdaq Listing Rule 5550(b)(1)), which requires the Company to maintain stockholders' equity of at least $2,500,000 for continued listing.
Material Changes and Listing Status
- Listing Exception Granted: On February 2, 2026, the Nasdaq Hearing Panel granted the Company an exception to cure listing deficiencies.
- Stockholders' Equity Deficiency: The Company previously failed to meet the $2.5 million equity requirement as of May 22, 2025, and received a delist determination letter on November 19, 2025.
- Annual Meeting Deficiency: The Company was non-compliant with the Annual Meeting Rule (Rule 5620(a)) after its 2025 annual meeting was adjourned due to a lack of quorum. The Company successfully held the meeting on January 30, 2026, curing this specific deficiency.
Guidance, Outlook, and Risks
Compliance Deadline: The Company must demonstrate compliance with the Stockholders' Equity Rule by March 30, 2026. This requires filing a timely public disclosure describing transactions undertaken to achieve compliance and demonstrating long-term compliance.
Risks and Contingencies: Management states there can be no assurance that the Company will be able to regain compliance with the Stockholders' Equity Rule or maintain compliance with all other Nasdaq continued listing requirements. Failure to meet the March 30, 2026 deadline could result in delisting.
Investor Verification Checklist
- Verify the Company's current stockholders' equity balance to assess the gap to the $2.5 million threshold.
- Monitor for public disclosures detailing specific capital raising transactions or other measures planned before March 30, 2026.
- Confirm the Company's ability to maintain compliance with other Nasdaq listing requirements beyond equity and annual meetings.
- Review subsequent filings for updates on the status of the equity cure plan.